Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2015 Dec 01; 33(34):4007-14.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Chemotherapy, Adjuvant
Double-Blind Method
ErbB Receptors
Erlotinib Hydrochloride
Female
Follow-Up Studies
Humans
International Agencies
Lung Neoplasms
Male
Middle Aged
Mutation
Neoplasm Staging
Prognosis
Survival Rate
Young Adult

authors with profiles

Philip Charles Hoffman